Publication date: Jul 17, 2024
To investigate the optimal gestational age to deliver pregnant people with chronic hypertension to improve perinatal outcomes. We conducted a planned secondary analysis of a randomized controlled trial of chronic hypertension treatment to different blood pressure goals. Participants with term, singleton gestations were included. Those with fetal anomalies and those with a diagnosis of preeclampsia before 37 weeks of gestation were excluded. The primary maternal composite outcome included death, serious morbidity (heart failure, stroke, encephalopathy, myocardial infarction, pulmonary edema, intensive care unit admission, intubation, renal failure), preeclampsia with severe features, hemorrhage requiring blood transfusion, or abruption. The primary neonatal outcome included fetal or neonatal death, respiratory support beyond oxygen mask, Apgar score less than 3 at 5 minutes, neonatal seizures, or suspected sepsis. Secondary outcomes included intrapartum cesarean birth, length of stay, neonatal intensive care unit admission, respiratory distress syndrome (RDS), transient tachypnea of the newborn, and hypoglycemia. Those with a planned delivery were compared with those expectantly managed at each gestational week. Adjusted odds ratios (aORs) with 95% CIs are reported. We included 1,417 participants with mild chronic hypertension; 305 (21. 5%) with a new diagnosis in pregnancy and 1,112 (78. 5%) with known preexisting hypertension. Groups differed by body mass index (BMI) and preexisting diabetes. In adjusted models, there was no association between planned delivery and the primary maternal or neonatal composite outcome in any gestational age week compared with expectant management. Planned delivery at 37 weeks of gestation was associated with RDS (7. 9% vs 3. 0%, aOR 2. 70, 95% CI, 1. 40-5. 22), and planned delivery at 37 and 38 weeks was associated with neonatal hypoglycemia (19. 4% vs 10. 7%, aOR 1. 97, 95% CI, 1. 27-3. 08 in week 37; 14. 4% vs 7. 7%, aOR 1. 82, 95% CI, 1. 06-3. 10 in week 38). Planned delivery in the early-term period compared with expectant management was not associated with a reduction in adverse maternal outcomes. However, it was associated with increased odds of some neonatal complications. Delivery timing for individuals with mild chronic hypertension should weigh maternal and neonatal outcomes in each gestational week but may be optimized by delivery at 39 weeks.
Concepts | Keywords |
---|---|
Diabetes | Chronic |
Gynecol | Compared |
Hemorrhage | Delivery |
Neonatal | Gestational |
Planned | Hypertension |
Included | |
Maternal | |
Mild | |
Neonatal | |
Outcome | |
Outcomes | |
Planned | |
Primary | |
Week | |
Weeks |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | Hypertension |
disease | IDO | blood |
disease | MESH | fetal anomalies |
disease | MESH | preeclampsia |
disease | MESH | death |
disease | MESH | morbidity |
disease | MESH | heart failure |
disease | MESH | stroke |
disease | MESH | encephalopathy |
disease | MESH | edema |
disease | MESH | renal failure |
disease | MESH | hemorrhage |
disease | MESH | neonatal death |
drug | DRUGBANK | Oxygen |
disease | MESH | sepsis |
disease | MESH | respiratory distress syndrome |
disease | MESH | transient tachypnea of the newborn |
disease | MESH | hypoglycemia |
disease | MESH | complications |